Labviva vs Genentech

Side-by-side comparison of AI visibility scores, market position, and capabilities

Labviva logo

Labviva

NicheLife Sciences & BioTech

Life Sciences Procurement Marketplace

Labviva is a digital procurement marketplace for life sciences researchers, connecting labs at academic institutions and biopharma companies with scientific suppliers; raised $22M Series A in 2022;

About

Labviva is a Boston-based life sciences technology company founded in 2017 by Lina Nilsson and Barry Bettman. It operates a digital procurement marketplace purpose-built for scientific researchers at pharmaceutical companies, biotech firms, academic research institutions, and hospitals. The platform aggregates product catalogs from thousands of scientific suppliers — including reagents, lab equipment, consumables, and biological materials — into a unified, searchable interface that integrates directly with institutional procurement and ERP systems such as SAP, Coupa, and Jaggaer. This eliminates the fragmented, email-and-catalog-driven purchasing workflows that dominate scientific procurement.

Full profile
Genentech logo

Genentech

LeaderLife Sciences & BioTech

Biopharmaceuticals

Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.

AI VisibilityBeta
Overall Score
A85
Category Rank
#1 of 2
AI Consensus
57%
Trend
up
Per Platform
ChatGPT
77
Perplexity
95
Gemini
83

About

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.

Full profile

Key Details

Category
Life Sciences Procurement Marketplace
Biopharmaceuticals
Tier
Niche
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Genentech
Biopharmaceuticals
Genentech is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.